- Home
- RARE vs INTA Comparison
RARE vs INTA Comparison
Compare RARE & INTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RARE | INTA |
|---|---|---|
| Founded | 2010 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.5B |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RARE | INTA |
|---|---|---|
| Price | $33.60 | $43.29 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 9 |
| Target Price | ★ $85.20 | $59.63 |
| AVG Volume (30 Days) | ★ 1.4M | 811.2K |
| Earning Date | 11-04-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $630,598,000.00 | $524,342,000.00 |
| Revenue This Year | $19.65 | $15.18 |
| Revenue Next Year | $23.65 | $13.48 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 20.63 | 17.11 |
| 52 Week Low | $25.81 | $35.51 |
| 52 Week High | $50.00 | $77.74 |
Technical Indicators
Market Signals| Indicator | RARE | INTA |
|---|---|---|
| Relative Strength Index (RSI) | 52.82 | 59.21 |
| Support Level | $32.06 | $41.78 |
| Resistance Level | $34.77 | $44.12 |
| Average True Range (ATR) | 1.40 | 1.66 |
| MACD | 0.08 | 0.21 |
| Stochastic Oscillator | 66.67 | 74.32 |
Price Performance
Historical ComparisonAbout RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About INTA Intapp Inc.
Intapp Inc is a provider of industry-specific, cloud-based software solutions for the professional and financial services industry. It empowers private capital,g, legal, accounting, and consulting firms with the technology needed to meet rapidly changing client, investor, and regulatory requirements. Geographically, it derives a majority of its revenue from the United States and also has a presence in the United Kingdom and the Rest of the world.